Pfizer Inc. (NYSE:PFE) Shares Acquired by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 762.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,095 shares of the biopharmaceutical company's stock after buying an additional 40,750 shares during the quarter. Hillsdale Investment Management Inc.'s holdings in Pfizer were worth $1,223,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Forefront Wealth Management Inc. bought a new position in Pfizer in the 4th quarter valued at $554,000. Sei Investments Co. grew its holdings in shares of Pfizer by 5.4% in the fourth quarter. Sei Investments Co. now owns 1,829,811 shares of the biopharmaceutical company's stock worth $48,545,000 after purchasing an additional 94,124 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Pfizer by 2.9% in the fourth quarter. American Century Companies Inc. now owns 2,679,628 shares of the biopharmaceutical company's stock worth $71,091,000 after purchasing an additional 75,245 shares during the last quarter. Plancorp LLC increased its stake in Pfizer by 3.1% in the 4th quarter. Plancorp LLC now owns 97,981 shares of the biopharmaceutical company's stock worth $2,599,000 after buying an additional 2,968 shares during the period. Finally, Mizuho Securities USA LLC lifted its holdings in Pfizer by 46.2% during the 4th quarter. Mizuho Securities USA LLC now owns 537,102 shares of the biopharmaceutical company's stock valued at $14,249,000 after buying an additional 169,647 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Down 0.6 %

PFE traded down $0.16 during trading on Thursday, hitting $25.05. The stock had a trading volume of 51,260,038 shares, compared to its average volume of 36,807,599. The stock has a 50 day simple moving average of $26.12 and a two-hundred day simple moving average of $26.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a market capitalization of $142.08 billion, a PE ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the business earned $0.10 EPS. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.